Commercial Due Diligence for a GCC Mid-Market Acquisition

GCC Private Equity at an Inflection Point

GCC private equity is undergoing a structural expansion. The regional PE market reached $4.2 billion in 2024 and is projected to nearly double to $7.6 billion by 2033. Total private capital financings across the GCC reached $54.8 billion in the 2020–2024 period — more than five times the $10.4 billion recorded in 2015–2019. GCC M&A activity surged 170% in 2025 to reach $72.7 billion across 554 transactions, with the UAE alone accounting for $60.4 billion.

The mid-market segment — deals valued between $50 million and $500 million — represents 45% of GCC PE activity by volume. It is the segment most directly served by independent consultants: large enough to require serious analytical rigour, but too time-constrained and cost-sensitive to sustain the pricing and pace of large-firm CDD engagements. When a fund is working within a 4-week exclusivity window, a 6–8 week traditional CDD timeline is not merely inconvenient — it is disqualifying.

The healthcare sector is one of the most active in GCC PE. Gulf Capital, one of the region's most established PE firms, lists healthcare as a top-priority sector. The GCC healthcare market is supported by structural demand drivers — rapidly growing and ageing populations, rising prevalence of chronic disease, government mandates to expand private-sector healthcare capacity — that insulate it from the cyclical volatility that affects other sectors. For a regional fund, a $120 million healthcare acquisition represents a high-conviction thesis in a well-understood sector. The question is execution risk, competitive dynamics, and management quality — exactly what CDD is designed to assess.

The Mandate

The fund — a mid-market PE vehicle with approximately $800 million in assets under management and a track record of three successful exits in the GCC — had identified a healthcare services platform operating across three GCC markets. The platform had strong revenue growth and an interesting consolidation thesis, but the fund's investment team lacked the sector depth to validate the commercial assumptions in the target's business plan.

Two large firms had been approached. Both proposed teams of six to eight consultants with 6–8 week timelines. One firm quoted a fee that, even at the discounted "relationship rate" offered to the fund, represented 1.8% of the transaction value. The fund's managing partner was explicit: they needed the analysis before the exclusivity period expired, not a week after it lapsed. Standard institutional CDD was not an option.

The Selectra Approach

Selectra identified and placed two consultants within five business days of receiving the brief. The healthcare specialist — a former Strategy& principal who had led commercial due diligence on seven healthcare transactions in the MENA region — had direct experience with the specific sub-segment in which the target operated and brought an existing model framework that could be adapted rather than built from scratch. The PE CDD generalist had executed more than 50 transactions across MENA and was familiar with the specific governance complexities and disclosure challenges that characterise GCC family-owned healthcare businesses.

The GCC-specific context required particular attention. Between 75% and 80% of GCC private sector companies are family-owned. Family business dynamics — succession uncertainty, informal governance, opaque related-party transactions, and the challenges of professionalising management while maintaining family harmony — represent the most significant due diligence risk in the regional mid-market. Only 44% of GCC family businesses have formal family employment policies. Fewer than one in five successfully transitions to a third generation. The management assessment component of the CDD was designed with these dynamics explicitly in mind.

The scope covered five areas: market demand verification (total addressable market, growth drivers, competitive dynamics, regulatory environment); competitive positioning (the target's market share, differentiation, and pricing power); management assessment (leadership capability, governance quality, key-person dependency, succession planning); business plan validation (revenue growth assumptions, cost structure benchmarking, EBITDA bridge analysis); and a 100-day value creation plan outlining the immediate operational priorities post-close.

The Bain EBITDA bridge methodology was applied to the value creation plan, with RAG scoring against 12 value creation levers across commercial acceleration, cost optimisation, and organisational strengthening.

Outcome and Impact

The full CDD report was delivered in three weeks — five days ahead of the exclusivity deadline, providing the fund's investment committee with sufficient time to review, ask questions, and make a considered decision. The report included a 200-page primary document and an IC-ready presentation deck with a clear investment recommendation, risk matrix, and value creation roadmap.

The fund proceeded with the acquisition. In Year 1 post-close, the portfolio company achieved EBITDA improvement of more than 200 basis points — consistent with the value creation plan's conservative case. The fund estimated the total cost of the Selectra-facilitated CDD at less than 30% of what the large-firm proposal would have cost, with faster delivery and, in the view of the fund's team, more actionable output. The healthcare specialist subsequently joined the fund's advisory network for portfolio company support.